Lupin Ltd

Lupin announced the launch of Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, in the United States, following the approval for its Abbreviated New Drug Application (ANDA) from the U.S. FDA. The product was developed in partnership with Pharmascience Inc. Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80mg, 100 mg, and 140 mg are bioequivalent to Sprycel' Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, of Bristol-Myers Squibb Company, and indicated for the treatment of: - newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase  - adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+CML with resistance or intolerance to prior therapy including imatinib  - adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy  - pediatric patients 1 year of age and older with Ph+ CML in chronic phase  - pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapyPowered by Capital Market - Live

TB Alliance is a non-profit drug developer. Under the terms of the agreement, Lupin and TB Alliance will collaborate to support the clinical development and commercialization of Telacebec, to provide advanced treatment options for patients affected by these diseases. TB Alliance will continue to lead the development process, while Lupin will provide its expertise in global manufacturing, regulatory affairs, and supply chain to ensure global access to Telacebec. Ramesh Swaminathan, executive director, Global CFO, and Head of IT and API Plus SBU, Lupin, said, 'This collaboration with TB Alliance underscores Lupin's enduring commitment to improving patient outcomes in areas of significant unmet medical need. By leveraging our manufacturing scale and global distribution capabilities alongside TB Alliance's deep expertise in drug development, we aim to enable timely and equitable access to Telacebec and contribute meaningfully to the global fight against tuberculosis, leprosy, and Buruli ulcer.' Mel Spigelman, managing director (MD), president and chief executive officer (CEO), TB Alliance, said, 'Telacebec represents the kind of scientific innovation that has the potential to transform treatment for diseases that have long been neglected. By partnering with Lupin, we are combining deep scientific expertise with global Chemistry, Manufacturing and Controls and access capabilities to help move this promising compound forward as quickly and responsibly as possible, with the ultimate goal of delivering better treatment options to people affected by tuberculosis, leprosy, and Buruli ulcer around the world.' Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company had reported a 73.33% surge in consolidated net profit to Rs 1,477.92 crore in Q2 FY26 as against Rs 852.63 crore posted in Q2 FY25. Revenue from operations jumped 24.27% year-on-year to Rs 6,831.43 crore in the quarter ended 30 September 2025. The counter declined 1.77% to Rs 2100.70 on the BSE.Powered by Capital Market - Live

Lupin announced a strategic collaboration with TB Alliance, a nonprofit drug developer, to advance the clinical development and commercialization of the investigational drug Telacebec (formerly known as Q203), for the treatment of multiple mycobacterial diseases including tuberculosis (TB), leprosy, and buruli ulcer. Under the terms of the agreement, Lupin and TB Alliance will collaborate to support the clinical development and commercialization of Telacebec, to provide advanced treatment options for patients affected by these diseases. TB Alliance will continue to lead the development process, while Lupin will provide its expertise in global manufacturing, regulatory affairs, and supply chain to ensure global access to Telacebec. Powered by Capital Market - Live

Lupin will hold a meeting of the Board of Directors of the Company on 12 February 2026.Powered by Capital Market - Live

Lupin has allotted 169,140 equity shares under ESOP on 27 January 2026. Consequently, the company also received another order from the Higher Education Department, Government of Odisha, for construction and renovation works across five state public universities under the GSU of PM-USHA scheme. The total value of this order is Rs 56.23 crore, with NBCC designated as the project management consultant. Powered by Capital Market - Live

Lupin today announced that it has received the highest 'A' leadership rating from Climate Disclosure Project (CDP) for its exceptional accomplishments in Climate Change and Water Security. This recognition affirms Lupin's position among distinguished global leaders who champion sustainability and transparency at the highest level. Lupin's double 'A' rating in Climate and Water exemplifies its steadfast commitment to sustainability and proactive initiatives aimed at mitigating climate risks, reducing carbon emissions, and ensuring responsible water management throughout its operations. This represents a substantial enhancement compared to Lupin's 2024 ratings of 'A-' in both categories, as well as the ratings of 'B' in 2023 for climate and 'C' for water, thereby reflecting significant year-over-year progress. Lupin has not only received recognition from CDP but also achieved an S&P Global ESG score of 91 in 2025. This is a best-in-class global achievement, positioning Lupin among a distinguished group of companies worldwide that have surpassed the 90-point threshold. Powered by Capital Market - Live

Lupin announced a licensing and supply agreement through its subsidiary Lupin Atlantis Holdings SA (LAHSA) with Galenicum Health, S.L.U. (Galenicum) for finished formulations of injectable Semaglutide, a GLP-1 receptor agonist. As per the agreement, Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally, including Canada, Europe, Southeast Asia and Latin America. Lupin is well-positioned to expand its leadership in diabetes care and obesity beyond India with this Semaglutide partnership. Semaglutide is a generic form of glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar and appetite. It is mainly prescribed for adults with Type 2 Diabetes, alongside diet and exercise, and is also used for long-term weight management in adults with obesity or overweight conditions. Powered by Capital Market - Live

According to an exchange filing, the agreement strengthens Lupin's diabetes portfolio and expands its presence in the obesity segment. Bofanglutide, developed by Gan & Lee, is intended for adults with type 2 diabetes and for weight management in overweight or obese individuals. As a potential first-in-class fortnightly GLP-1 agonist, clinical data indicate that Bofanglutide delivers weight loss results comparable to or better than existing GLP-1 alternatives, with the added convenience of once-every-two-weeks dosing compared to weekly injections, while maintaining safety and tolerability consistent with the GLP-1 class. The drug also helps reduce blood glucose levels and body weight. The company said obesity is emerging as a major health concern in India, with an estimated 174 million adults overweight and around 50 million classified as obese. Diabetes affects approximately 90 million adults in the country. Under the terms of the agreement, Lupin will have exclusive rights to commercialize and distribute Bofanglutide in India. Nilesh Gupta, Managing Director, Lupin, said, 'We are committed to offering the best solutions for managing chronic metabolic diseases like diabetes, and addressing obesity is one of the most urgent global health challenges. This partnership demonstrates our strategic focus on the GLP-1 class of drugs and highlights our dedication to delivering high-quality, innovative therapies for our patients.' Rajeev Sibal, President of India Region Formulations at Lupin, said, 'Bofanglutide offers a significant advantage with its convenient fortnightly dosing, thus reducing the number of injections by 50% while delivering outcomes and clinically proven efficacy that matches or surpasses existing weekly formulations. This strategic alliance marks a pivotal step in strengthening Lupin's leadership in metabolic health, expanding our innovative portfolio, and reaffirming our commitment to delivering transformative solutions.' Gan & Lee Executive Vice President & Chief Commercial Officer (EVP & CCO) Kai Du and Key Accounts Director, Dr Dhaval Soneji commented and believed, 'On the heels of the Latin American exclusive agreement signed in November, this new partnership with Lupin for the Indian market further underscores Gan & Lee's rapid global strategic advancement. Our goal is to provide superior treatment options for patients with metabolic diseases worldwide, while showcasing the value of Chinese biopharmaceutical innovation on the global stage.' Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company had reported a 73.33% surge in consolidated net profit to Rs 1,477.92 crore in Q2 FY26 as against Rs 852.63 crore posted in Q2 FY25. Revenue from operations jumped 24.27% year-on-year to Rs 6,831.43 crore in the quarter ended 30 September 2025. The counter rose 0.11% to currently trade at Rs 2,081.80 on the BSE. Powered by Capital Market - Live

Lupin has entered into an exclusive License, Supply and Distribution agreement with Gan & Lee Pharmaceuticals, headquartered in China, for a novel fortnightly GLP-1 receptor agonist, Bofanglutide. The agreement strengthens Lupin's diabetes portfolio and accelerates its presence in the obesity segment. Bofanglutide injection is a fortnightly (once in two weeks) GLP-1 receptor agonist developed by Gan & Lee, intended for treating adults with type 2 diabetes and aiding weight management in overweight or obese individuals. As a potential first-in-class global fortnightly GLP-1 agonist, clinical data demonstrate that the weight loss results of Bofanglutide are comparable to or better than those of existing GLP-1 alternatives while offering the convenience of once in two weeks versus once a week for other injectable alternatives, and maintaining safety and tolerability consistent with the GLP-1 class. It effectively reduces both blood glucose levels and body weight. Obesity is anticipated to develop into a significant health crisis in India, with approximately 174 million adults classified as overweight and around 50 million as obese. Diabetes is already considered an epidemic, with approximately 90 million adults affected by the condition. Under the terms of the agreement, Lupin will have exclusive rights to commercialize and distribute Bofanglutide in India. Powered by Capital Market - Live

The EIR was issued following an inspection of the facility from 08 September 2025 to 16 September 2025. Nilesh Gupta, managing director, Lupin, said: 'We are pleased to have received the EIR from the U.S. FDA with a VAI classification for our Nagpur injectable facility. We are committed to upholding the highest standards of quality and compliance across our facilities, with continued focus on enhancements to our quality systems and operational excellence.' Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company had reported a 73.33% surge in consolidated net profit to Rs 1,477.92 crore in Q2 FY26 as against Rs 852.63 crore posted in Q2 FY25. Revenue from operations jumped 24.27% year-on-year to Rs 6,831.43 crore in the quarter ended 30 September 2025. The counter rose 0.84% to currently trade at Rs 2107.20 on the BSE. Powered by Capital Market - Live